UK pharma group posts ‘statistically significant’ trial results for treatment combined with Blenrep pulled in 2022 ...
(Alliance News) - GSK PLC on Thursday said its Blenrep drug has shown overall survival benefits in patients with relapsed or refractory multiple myeloma, the third most common type of blood cancer.
After years of limited advancements in chronic obstructive pulmonary disease (COPD) treatment, patients now have new options.
As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...
GSK added Ojjaara to its portfolio through the acquisition of Sierra in 2022. Credit: Magda Wygralak via Shutterstock. Health ...